相关实验视频
Updated: Jan 14, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.9K
在动脉样硬化中,APOE4通过胆固醇促进尼格拉高酸化
Shanshan Hu1, Xiaojia Peng2, Bing Xia3
1Good Clinical Practice Center, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China. hsjixu@163.com.
Cell death discovery
|October 21, 2025
概括
患有动脉样硬化症的阿波利波蛋白E4 (APOE4) 载体显示大脑tau病理增加. 准胆固醇可能会减轻帕金森氏症.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 遗传学 遗传学 是一个
背景情况:
- 尼格拉的过酸化启动了尼格罗斯特里塔尔多巴胺基神经退行.
- 阿波脂蛋白E4基因 (APOE4) 是帕金森病 (PD) 和动脉样硬化 (AS) 的危险因素.
- APOE4,AS和PD相关的病之间的联系尚不清楚.
研究的目的:
- 调查APOE4载体是否具有较高的化酸 (p-tau) 水平.
- 探索AS和PD相关的病之间的相关性.
- 为了确定向胆固醇是否可以减轻神经退行.
主要方法:
- 在AS患者的死后大脑分析 (APOE4携带者与非携带者).
- 高脂肪饮食 (HFD) 诱导AS模型在APOE3/3和APOE4/4敲进小鼠中.
- 对神经病理,胆固醇积累,AS斑块区域和行为测试的分析.
- 在实验室中对初级神经元进行研究,以评估胆固醇在陶酸化中的作用.
主要成果:
- 携带APOE4的AS患者表现出较高的尼格拉尔p-tau.
- 与APOE3小鼠相比,HFD的APOE4小鼠表现出增加的p-tau,胆固醇和AS斑块.
- 胆固醇触发了GSK3β的激活,导致神经元中的陶酸化.
- 减轻胆固醇的运输减少了黑色胆固醇,病理和黑色状细胞退化.
结论:
- 在APOE4载体中,尼格拉病理与AS表型之间存在联系.
- 胆固醇的积累加剧了黑色物质中的毛病和神经退行.
- 向胆固醇新陈代谢可能为AS和PD类陶病症提供治疗策略.
相关概念视频
01:30Atherosclerosis I: Introduction
904
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
904
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:38Inflammation
61.6K
Overview
61.6K
01:22Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
01:26Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
01:29Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K